GlassScriptPhysician profile
Andy Alnajjar
NPI 1770164972
$4,515.28
in general payments reported to CMS, 2019-2025
27 companies · $2,132 in 2025
The $2,132 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $611 · 2023: $642 · 2024: $1,131 · 2025: $2,132.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,904.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,904.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,130.52 | 2022-2025 | Airsupra, Fasenra, Farxiga |
| Pfizer INC. | $433.92 | 2024-2025 | |
| Glaxosmithkline, LLC. | $428.57 | 2024-2025 | Arexvy, Penmenvy, Trelegy Ellipta |
| Novo Nordisk INC | $417.11 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Genzyme Corporation | $407.67 | 2022-2024 | |
| Abbvie INC. | $338.73 | 2023-2025 | Vraylar, Botox |
| Arcutis Biotherapeutics, INC. | $220.64 | 2023-2024 | Zoryve |
| Lilly USA, LLC | $178.84 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $166.33 | 2025 | Repatha, Repatha, Otezla |
| Actelion Pharmaceuticals US, INC. | $129.59 | 2024-2025 | Opsumit, Uptravi |
| Exact Sciences Corporation | $111.80 | 2024-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $109.18 | 2025 | Capvaxive |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $106.31 | 2024-2025 | Xifaxan |
| Amneal Pharmaceuticals LLC | $49.04 | 2025 | Unithroid |
| Phathom Pharmaceuticals, INC. | $34.28 | 2025 | Voquezna |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $28.81 | 2025 | Rexulti |
| Biogen, INC. | $25.65 | 2025 | Skyclarys |
| Biohaven Pharmaceutical Holding Company LTD. | $24.25 | 2022 | |
| Organon LLC | $23.90 | 2022 | |
| Sanofi-Aventis U.S. LLC | $23.48 | 2025 | |
| Axsome Therapeutics, INC. | $22.58 | 2025 | Auvelity |
| Astellas Pharma US INC | $21.68 | 2025 | Veozah |
| Sun Pharmaceutical Industries INC. | $20.81 | 2022 | |
| Alk-Abello, INC | $19.81 | 2025 | Neffy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.98 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.33 | 2022 | |
| Tms Neurohealth Centers INC. | $11.47 | 2025 | Tms Neurohealth Centers INC. |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andy Alnajjar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.